Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2011

01-12-2011 | Poster presentation

BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients

Authors: K Bouchalova, M Cizkova, R Trojanec, V Koudelakova, L Radova, J Furstova, B Melichar, K Cwiertka, G Kharaishvili, Z Kolar, M Hajduch

Published in: Breast Cancer Research | Special Issue 2/2011

Login to get access

Excerpt

Triple-negative breast cancers (TNBCS) are aggressive with poor prognosis. Patients cannot benefit from targeted treatment. Moreover, little is known of which TNBC patients will benefit from nontargeted adjuvant treatment. The objective was to search for predictors of adjuvant chemotherapy in TNBC. …
Metadata
Title
BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients
Authors
K Bouchalova
M Cizkova
R Trojanec
V Koudelakova
L Radova
J Furstova
B Melichar
K Cwiertka
G Kharaishvili
Z Kolar
M Hajduch
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3029

Other articles of this Special Issue 2/2011

Breast Cancer Research 2/2011 Go to the issue

Poster presentation

Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin

Poster presentation

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Poster presentation

Quantitative proteomics reveals novel proteins and central pathways associated with endocrine resistance in breast cancer

Oral presentation

Molecular classification of triple-negative tumors

Poster presentation

Oestrogen receptor status predicts for local recurrence following wide local excision for breast tumours

Oral presentation

Design of RESILIENCE: a phase 3 trial comparing capecitabine in combination with sorafenib or placebo for treatment of locally advanced or metastatic HER2-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits